Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19592076 | 0.79 | TSHR (0.33) | NPSR1 | |
| SCHEMBL22151601 | 0.71 | ADORA2A (0.42) | ADORA2AADORA2BMAPT | |
| SCHEMBL17045354 | 0.69 | ADORA2A (0.35) | ADORA2AADORA2BMEN1MAPTRAB9A | |
| SCHEMBL13341968 | 0.68 | MAPT (0.42) | ADORA2AADORA2BMAPTNPSR1 | |
| SCHEMBL23400861 | 0.68 | ADORA2A (0.41) | ADORA2AADORA2B | |
| SCHEMBL6107224 | 0.66 | PLAT (0.41) | ADORA2AADORA2BMEN1MAPTRAB9A | |
| SCHEMBL18159972 | 0.66 | MAPT (0.43) | MEN1MAPTRAB9AKMT2ANPSR1 | |
| SCHEMBL6103830 | 0.65 | PLAT (0.40) | ADORA2AADORA2B | |
| SCHEMBL16809980 | 0.64 | ARF6 (0.35) | — | |
| SCHEMBL23502029 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815791-B2 | Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160304465-A1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304465-A1 | ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | ADORA2A 313/4885ADORA2B 326/4885CCNE1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.